Cargando…

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus

Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections and the most frequent invasive infection due to methicillin-resistant S. aureus (MRSA). Treatment is challenging, particularly for MRSA, because of limited treatment options. Telavancin is a bactericidal li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corey, G. Ralph, Rubinstein, Ethan, Stryjewski, Martin E., Bassetti, Matteo, Barriere, Steven L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Invited Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329924/ https://www.ncbi.nlm.nih.gov/pubmed/25472944 http://dx.doi.org/10.1093/cid/ciu971

Ejemplares similares

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
por: Barriere, Steven L, et al.
Publicado: (2014)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

Reply to Tarchini
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Platelet and Neutrophil Responses to Gram Positive Pathogens in Patients with Bacteremic Infection
por: Johansson, Daniel, et al.
Publicado: (2011)

Associations of pathogen‐specific and host‐specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia
por: Sharma‐Kuinkel, Batu K, et al.
Publicado: (2019)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Staphylococcus aureus and Chronic Airway Disease
por: Derycke, Lara, et al.
Publicado: (2010)

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
por: Roch, Melanie, et al.
Publicado: (2018)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients
por: Maor, Yasmin, et al.
Publicado: (2009)

A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus
por: Rajamuthiah, Rajmohan, et al.
Publicado: (2015)

Epidemiology and risk factors for mortality among methicillin-resistant Staphylococcus aureus bacteremic patients in Southern Brazil
por: Riche, Cezar Vinícius Würdig, et al.
Publicado: (2023)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus
por: Yim, Juwon, et al.
Publicado: (2016)

Effectiveness of oral cephalexin in antibiotic-course completion for methicillin-susceptible Staphylococcus aureus-induced bacteremic vertebral osteomyelitis
por: Okumura, Nobumasa, et al.
Publicado: (2023)

Complement levels in patients with bloodstream infection due to Staphylococcus aureus or Gram-negative bacteria
por: Eichenberger, Emily M., et al.
Publicado: (2020)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
por: Matsumoto, Tetsuya
Publicado: (2014)

Treatment of Infections Due to MDR Gram-Negative Bacteria
por: Bassetti, Matteo, et al.
Publicado: (2019)

Therapeutic neutralization of interferon-gamma in primates prevents lethality in Gram-negative bacteremic shock
por: Lainée, P, et al.
Publicado: (2004)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis
por: Mubareka, Samira, et al.
Publicado: (2005)

High prevalence of spa type t571 among methicillin-susceptible Staphylococcus aureus from bacteremic patients in a French University Hospital
por: Bonnet, Isabelle, et al.
Publicado: (2018)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8i3ufl50mrub7tlg4tgbfpglfr